Skip to main content
SpringerLink
Log in

Nonmyeloablative Hematopoietic Cell Transplantation: Status Quo and Future Perspectives

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

In nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT), high-dose cytotoxic therapy as the conceptual basis for treating hematopoietic malignancies has been replaced by graft-versus-tumor effects. The use of potent pre- and postgrafting immunosuppression derived from preclinical studies has allowed omission of myeloablative cytotoxic therapy without compromising hematopoietic donor cell engraftment. This results in a marked reduction in transplant-related toxicities that makes older or medically infirm patients candidates for this treatment option. This patient group is more representative of the population with cancer and would have been ineligible for conventional HSCT. Initial results in patients with a variety of hematologic malignancies have been encouraging with documented sustained cytogenetic and molecular remissions in a substantial number of sometimes heavily pretreated and previously refractory patients. Even though patients with hematologic malignancies will likely require conversion to full donor hematopoiesis for long-term disease control, a state of mixed hematopoietic chimerism might suffice to “cure” the disease phenotypes in various nonmalignant diseases. Strategies aimed at optimizing peritransplant immunosuppression may eventually eliminate the need for pretransplant total body irradiation, which is relevant for minimizing late toxicities. Enhancing graft-versus-tumor effects by virtue of postgrafting vaccination of recipients against tumor-specific antigens may help to use this transplant approach more effectively in the treatment of solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation. N Engl J Med 292:832–843, 895‐902, 1975

    Google Scholar 

  2. Gorin NC, Labopin M, Fouillard L, Meloni G, Frassoni F, Iriondo A, Brunet MS, Goldstone AH, Harousseau JL, Reiffers J, Esperou-Bourdeau H, Gluckman E: Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. Bone Marrow Transplant 18:111–117, 1996

    Google Scholar 

  3. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217–223, 1995

    Google Scholar 

  4. Fefer A, Sullivan KM, Weiden P, Buckner CD, Schoch G, Storb R, Thomas ED: Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow, transplantation. In Cellular Immunotherapy of Cancer, RL Truitt, RP Gale, MM Bortin (eds). New York, Alan R. Liss, Inc, 1987, pp 401–408

    Google Scholar 

  5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562, 1990

    Google Scholar 

  6. Butturini A, Bortin MM, Gale RP: Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 2: 233–242, 1987

    Google Scholar 

  7. Ringden O, Horowitz MM: Graft-versus-leukemia reactions in humans. Transplant Proc 21:2989–2992, 1989

    Google Scholar 

  8. Sullivan KM, Fefer A, Witherspoon R, Storb R, Buckner CD, Weiden P, Schoch G, Thomas ED: Graft-versus-leukemia in man: Relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. In Cellular Immunotherapy of Cancer, RL Truitt, RP Gale, MM Bortin (eds). New York, Alan R. Liss, Inc, 1987, pp 391–399

    Google Scholar 

  9. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED: Influence of acute and chronic graftversus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728, 1989

    Google Scholar 

  10. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068–1073, 1979

    Google Scholar 

  11. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, and the Seattle Marrow Transplant Team: Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529–1533, 1981

    Google Scholar 

  12. Collins RH, Jr., Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, HuW, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433–444, 1997

    Google Scholar 

  13. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flombenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82:2310–2318, 1993

    Google Scholar 

  14. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, De Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041–2050, 1995

    Google Scholar 

  15. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261–1268, 1995

    Google Scholar 

  16. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100–106, 1994

    Google Scholar 

  17. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377–3383, 1994

    Google Scholar 

  18. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, Leisenring W. Shulman H: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048–3054, 1997

    Google Scholar 

  19. Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, McSweeney P, Seidel K, Georges G, Zaucha JM: Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 94:1131–1136, 1999

    Google Scholar 

  20. Storb R, Yu C, McSweeney P: Mixed chimerism after transplantation of allogeneic hematopoietic cells. In Hematopoietic Cell Transplantation, 2nd ed, ED Thomas, KG Blume, SJ Forman (eds). Boston, Blackwell Science; 1999, pp 287–295

    Google Scholar 

  21. Storb R: Nonmyeloablative preparative regimens: Experimental data and clinical practice. In ASCO Education Book, MC Perry (ed). 1999, pp 241–249

  22. McSweeney P, Storb R: Hematopoietic stem cell transplantation for malignant disease. In Clinical Immunology: Principles and Practice, RR Rich, TA Fleisher, WT Shearer, BL Kotzin, HW Schroeder, Jr. (eds). London, Harcourt Publishers Limited, 2001, pp 102.1–102.17

    Google Scholar 

  23. Sandmaier BM, Maloney DG, Hegenbart U, McSweeney PA, Shizuru J, Sahebi F, Chauncey T, Radich J, Maris M, Molina A, Blume K, Forman S, Niederwieser D, Storb R: Nonmyeloablative conditioning for HLA-identical related allografts for hematologic malignancies. Blood 96 (Part 1):479a, #2062, 2000 (Abstract)

    Google Scholar 

  24. Sandmaier BM, Niederwieser D, McSweeney PA, Shizuru J, Maloney DG, Radich J, Chauncey T, Deininger M, Blume KG, Storb R: Induction of molecular remissions in chronic myeloge-nous leukemia (CML) with nonmyeloablative HLA-identical sibling allografts. Blood 96 (Part 1):201a, #861, 2000 (Abstract)

    Google Scholar 

  25. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers MED, Georges GE, Grumet FC, Kiem H-P, Torok-Storb B, Yu C, Blume KG, Storb RF: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus-tumor effects. Blood 97:3390–3400, 2001

    Google Scholar 

  26. Niederwieser D, Maris M, Hegenbart U, Sandmaier B, Mc-Sweeney P, Poöisch W, Uharek L, Deininger M, Edelmann J, Kamprath F, Shizuru JA, Blume K, Storb R: Allogeneic unrelated hematopoietic stem cell transplants (HSCT) after conditioning with 2 Gy total body irradiation (TBI), fludarabine (FLU) and a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) in patients ineligible for conventional transplants. Blood 96 (Part 1):413a, #1778, 2000 (Abstract)

    Google Scholar 

  27. Maloney DG, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Molina AJ, Bensinger W, McSweeney PA, Storer BE, Niederwieser D, Chauncey T, Appelbaum FR, Blume KG, Forman SJ, Storb R: Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood 98 (Part 1): 434a, #1822, 2001 (Abstract)

    Google Scholar 

  28. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett J: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–758, 2000

    Google Scholar 

  29. Zaucha JM, Mielcarek M, Storb R, Zellmer E, Torok-Storb B: G-CSF mobilized peripheral blood mononuclear cells facilitate the development of stable mixed hematopoietic chimerism in dogs conditioned with only 100 cGy of irradiation. Blood 94(Suppl. 1):319a, #1425, 1999 (Abstract)

    Google Scholar 

  30. Zaucha JM, Zellmer E, Georges G, Little M-T, Storb R, Storer B, Torok-Storb B: G-CSF mobilized peripheral blood mononuclear cells (G-PBMC) added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplantation

  31. Saito K, Sakurai J, Ohata J, Kohsaka T, Hashimoto H, Okumura K, Abe R, Azuma M: Involvement of CD40 ligand-CD40 and CTLA4‐B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol 160: 4225–4231, 1998

    Google Scholar 

  32. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C: CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 164:4564–4568, 2000

    Google Scholar 

  33. Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem H-P, Nash RA, McSweeney PA, Wagner JL: Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 94:2523–2529, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, USA

    Marco Mielcarek, Brenda M. Sandmaier, David G. Maloney & Michael Maris

  2. University of Colorado, Denver, Colorado

    Peter A. McSweeney, Ann Woolfrey, Thomas Chauncey, Lyle Feinstein, Beverly Torok-Storb & Rainer Storb

  3. University of Leipzig, Leipzig, Germany

    Dietger Niederwieser

  4. Stanford University School of Medicine, Stanford, California

    Karl G. Blume

  5. City of Hope National Medical Center, Duarte, California

    Stephen Forman

Authors
  1. Marco Mielcarek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brenda M. Sandmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David G. Maloney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Maris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter A. McSweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ann Woolfrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas Chauncey
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lyle Feinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dietger Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Karl G. Blume
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Stephen Forman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Beverly Torok-Storb
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rainer Storb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Mielcarek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mielcarek, M., Sandmaier, B.M., Maloney, D.G. et al. Nonmyeloablative Hematopoietic Cell Transplantation: Status Quo and Future Perspectives. J Clin Immunol 22, 70–74 (2002). https://doi.org/10.1023/A:1014532401666

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1014532401666

Search

Navigation